!!John Geddes - Curriculum Vitae
\\
__CURRENT POSITIONS:__
\\ \\
1. WA Handley Professor of Psychiatry, University of Oxford\\
2. Fellow, Merton College, Oxford  (from Nov 1st 2021)\\
3. Director, NIHR Oxford Health Biomedical Research Centre, April 2017 - present \\
4. Honorary Consultant Psychiatrist, Oxford Health NHS Foundation Trust, Oxfordshire, UK 1995 - present\\
\\
__PREVIOUS POSITIONS:__
\\
*Director,  NIHR Oxford Cognitive Health Clinical Research Facility, Oxford University Hospitals NHS Foundation Trust 2011 - 2019 
*Director of R&D, Oxford Health NHS Foundation Trust 2011 - June 2021 \\
*Professor of Epidemiological Psychiatry and Senior Clinical Research Fellow, University of Oxford 2002 - Oct 31st 2021\\
*Head of Department of Psychiatry, University of Oxford 2011 - Sept 30th 202
\\
__QUALIFICATIONS:__
\\
*1985  MB ChB, University of Leeds \\
*1989 Member, Royal College of Psychiatrists\\
*1993 MD, University of Leeds \\
*2000    Fellow, Royal College of Psychiatrists
\\
ORCID: 0000-0002-5281-5960; H-index: Scopus 75\\
\\
__CURRENT RESEARCH GRANTS:__\\
\\
1. 2022-2027 Principal Investigator/Director NIHR Oxford Health Biomedical Research Centre (£35M)\\
\\
2. 2020-2021 Co-applicant: DHSC/UKRI COVID-19 Rapid Response Initiative: Post-hospitalisation COVID-19 study: a national consortium to understand and improve long-term health outcomes (PHOSP-COVID) £8.4 million\\
\\
3. 2018-2023: Co-investigatorNIHR Efficacy and Mechanism Evaluation Pramipexole in Treatment resistant depression (PAX-D) £2.5 million\\
\\
4. 2018-2023 Co-Applicant: NIHR Health Technology Assessment   Pramipexole in Bipolar Depression (PAX-BD) RCT £1.5 million\\
\\
5. 2017-2022 Co-Applicant NIHR Programme Grant for Applied Research TACKling chronic depression - adapting and testing a technology supported patient-centred and solution-focused intervention (DIALOG+) for people with chronic depression (TACK) £2,487,369\\
\\
6. 2017-2022 Co-Applicant  Canadian Institutes of Health Research (CIHR) Predicting the onset of bipolar disorder: A longitudinal high-risk study 950,000 CAD\\
\\
7. 2018-2021 Co-Applicant NIHR Invention for Innovation (i4i)  Immersive virtual reality to transform the lives of patients with psychosis  £3,994,595\\
\\
8. 2017-2022 Co-Applicant NIHR Health Technology Assessment   Lithium versus Quetiapine in Depression (LQD) RCT £1.5 million\\ \\[{ALLOW view All}][{ALLOW edit jgeddes}][{ALLOW upload jgeddes}][{ALLOW comment All}]
[{ALLOW view All}][{ALLOW edit jgeddes}][{ALLOW upload jgeddes}][{ALLOW comment All}]